Israeli Pharma Firm NeuroRx Completes SPAC Merger at $1.5B Valuation
By NoCamels Team
May 31, 2021 2 minutes
Health & ScienceNews Briefs
This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by coronaviruses CDC/ Alissa Eckert, MS; Dan Higgins, MAM. Wikimedia Commons
Israeli clinical-stage small molecule pharmaceutical company NeuroRx has announced the completion of a merger with Big Rock Partners Acquisition Corporation, a special purpose acquisition (SPAC) company. The company will trade on the NASDAQ as NRXP.
The deal is estimated to be worth a $1.5 billion valuation, the Haifa-based company said.
Founded in 2014, NeuroRx is a clinical-stage small molecule pharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary disease. The company’s two primary medicines are ZYESAMI (aviptadil), an application for COVID-19-related
Share this article
Share this article
RADNOR, Pa., May 25, 2021 /PRNewswire/ Today, NeuroRx, Inc., announced it has been approved by the Nasdaq for listing on the Nasdaq Global Market, following the completion of its business combination with Big Rock Partners Acquisition Corp. (Nasdaq:BRPA). The combined entity is NRx Pharmaceuticals, Inc. and will trade on the Nasdaq Global Market as NRXP. Today marks a major milestone as we include public investors in our quest to bring innovative medicines to patients at immediate risk of death, who have no currently-approved medicinal therapies. We live by our credo of Bringing Hope to Life, said Professor Jonathan Javitt, MD, MPH, Founder, CEO and Chairman of the Board, of NRx. We are indebted to the leaders and shareholders of BRPA who have chosen to support our mission.
Designated ‘Breakthrough Therapies’ draw support from Calyx The company’s medical imaging technology and other eClinical solutions reportedly played a part in half of the treatments to receive the FDA designation.
eClinical and regulatory services specialist Calyx reports that its medical imaging services and other eClinical solutions were used in approximately half of the oncology treatments approved by the US Food and Drug Administration (FDA) as Breakthrough Therapies over the past two years. This designation enables the agency to grant priority review to drug candidates if preliminary clinical trials indicate the therapy has potential to offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases.
Calyx Supports Breakthrough Therapy Approvals for Oncology Treatments
Calyx Medical Imaging and other eClinical services provide critical support for clinical development programs to deliver much-needed therapies to market.
News provided by
Share this article
Share this article
NOTTINGHAM, England, Jan. 19, 2021 /PRNewswire/ Calyx, the eClinical and regulatory solutions and services provider most relied on for solving complex data challenges in clinical research, today announced that its Medical Imaging and other eClinical solutions supported half of the oncology treatments approved by the FDA as Breakthrough Therapies in the past two years.
Calyx CEO, Gavin Nichols, discusses how Calyx s Medical Imaging and eClinical solutions are helping the biopharmaceutical industry bring much-needed oncology and other life-saving treatments to patients sooner.